Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 26 2024
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points and the Dow down 0.40%. The S&P 500 also fell by 0.53%, while initial jobless claims decreased to 219,000, lower than market expectations.
Market Movements in Commodities and Asia: Oil and gold prices saw slight increases, while Asian markets mostly closed higher, with Japan's Nikkei 225 gaining 1.12%. Notable stock movements included significant gains for Millennium Group International Holdings and Zoomcar Holdings, contrasted by sharp declines for Neuphoria Therapeutics and Baosheng Media Group.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeuroThera Acquires 54% Stake in CliniQuantum
- Acquisition Overview: NeuroThera Labs has completed the acquisition of approximately 54% of CliniQuantum's shares, involving 56,375 ordinary shares valued at approximately CAD$9,459,954.20, indicating the company's intent to expand in the central nervous system disorder treatment sector.
- Potential Earn-Out Structure: Selling shareholders may receive up to US$2,500,000 in earn-out payments contingent on patent applications and fundraising milestones, which not only incentivizes technological development but also enhances NeuroThera's competitive position in the market.
- License Agreement Significance: CliniQuantum holds an exclusive license agreement with Quantum X Labs concerning patents for quantum simulation and clinical trial data analysis, aimed at improving the precision of clinical trial outcomes, thereby strengthening the company's technological edge in innovative drug development.
- Shareholder Lock-Up Provisions: The transaction includes provisions for a floor price on future share issuances and lock-up arrangements for selling shareholders, which not only comply with TSX policy requirements but also provide assurance for future capital operations, thereby boosting investor confidence.
See More
Biotech Stocks Pre-Market Trading Update
- Significant Pre-Market Gains: SciSparc Ltd. (SPRC) surged 49% to $14.09 in pre-market trading, indicating strong investor interest likely driven by recent acquisition activities, which could enhance its market position.
- Other Gaining Stocks: Mobix Labs, Inc. (MOBX) rose 26% to $2.78, while Moolec Science SA. (MLEC) increased 14% to $9.22, reflecting positive sentiment in the biotech sector that may attract further investment.
- Pre-Market Decliners: ADC Therapeutics SA. (ADCT) plummeted 53% to $1.44, signaling market disappointment over its clinical trial results, which could lead to diminished investor confidence.
- Additional Declining Stocks: Basel Medical Group Ltd. (BMGL) fell 24% to $0.49, and Virax Biolabs Group Limited. (VRAX) dropped 17% to $0.19, highlighting the uncertainty in the biotech industry that may affect overall market sentiment.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
SciSparc Subsidiary Receives Approval for CliniQuantum Acquisition
- Stock Surge: SciSparc Ltd. (SPRC) saw a 155% increase in stock price on Thursday, primarily driven by its subsidiary NeuroThera Labs receiving conditional approval from the TSX Venture Exchange for its acquisition, reflecting strong market optimism about the deal.
- Acquisition Details: NeuroThera plans to acquire approximately 54% of CliniQuantum in exchange for 56.6 million common shares, valued at about $9.46 million based on NeuroThera's 20-day volume-weighted average share price, indicating market recognition of its growth potential.
- Technological Innovation: CliniQuantum focuses on developing quantum simulation and Monte Carlo-based tools aimed at enhancing clinical trial precision by identifying patient subgroups most likely to respond to therapies, showcasing its cutting-edge position in clinical research.
- Exclusive Licensing Agreement: CliniQuantum's main asset is an exclusive worldwide license agreement with Quantum X Labs related to quantum simulation technologies for clinical trials, which will further strengthen its market competitiveness and drive future technological advancements.
See More
SciSparc Acquires Controlling Interest in CliniQuantum
- Transaction Overview: SciSparc's majority-owned NeuroThera Labs has signed a share purchase agreement to acquire approximately 54.01% of CliniQuantum's shares for about $9.45 million, with the transaction expected to close within 30 days, marking a strategic expansion into quantum technology.
- Share Payment Structure: NeuroThera will issue 56,600,000 common shares to the Selling Shareholders, who may also receive up to $2.5 million in earn-out payments based on CliniQuantum's patent applications and fundraising achievements, further incentivizing innovation.
- Technological Innovation Potential: CliniQuantum focuses on leveraging quantum computing to enhance clinical trials, aiming to accelerate research by processing complex datasets, and this acquisition will strengthen SciSparc's competitive edge in the pharmaceutical industry and drive cutting-edge product development.
- Future Outlook: The transaction is anticipated to close by March 31, 2026, providing SciSparc an opportunity to enhance its market position in treating central nervous system disorders and achieve long-term growth through technological integration.
See More
Clearmind Unveils Patent for Innovative Weight Loss Therapy
- Patent for Innovative Therapy: Clearmind Medicine Inc. has announced an international patent application for a novel therapy combining MEAI and Palmitoylethanolamide, aimed at treating obesity and metabolic dysfunction-associated steatotic liver disease, potentially benefiting over 890 million obese adults worldwide.
- Significant Market Potential: The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, indicating a strong demand for innovative alternatives, positioning Clearmind's new therapy to capture a share of this rapidly growing market.
- Strengthened Partnerships: The development of this therapy is bolstered by collaboration with NeuroThera Labs Inc., integrating Clearmind's MEAI platform with PEA to offer a safer and more cost-effective treatment option compared to GLP-1 agonists, enhancing the company's competitive edge in the biotech sector.
- Strategic Development Focus: CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to developing innovative therapies to address underserved metabolic and neurological health issues, further solidifying its leadership position in the biotechnology industry.
See More
NeuroThera Acquires 54% Stake in CliniQuantum
- Acquisition Overview: NeuroThera Labs has completed the acquisition of approximately 54% of CliniQuantum's shares, involving 56,375 ordinary shares valued at approximately CAD$9,459,954.20, indicating the company's intent to expand in the central nervous system disorder treatment sector.
- Potential Earn-Out Structure: Selling shareholders may receive up to US$2,500,000 in earn-out payments contingent on patent applications and fundraising milestones, which not only incentivizes technological development but also enhances NeuroThera's competitive position in the market.
- License Agreement Significance: CliniQuantum holds an exclusive license agreement with Quantum X Labs concerning patents for quantum simulation and clinical trial data analysis, aimed at improving the precision of clinical trial outcomes, thereby strengthening the company's technological edge in innovative drug development.
- Shareholder Lock-Up Provisions: The transaction includes provisions for a floor price on future share issuances and lock-up arrangements for selling shareholders, which not only comply with TSX policy requirements but also provide assurance for future capital operations, thereby boosting investor confidence.
See More
Biotech Stocks Pre-Market Trading Update
- Significant Pre-Market Gains: SciSparc Ltd. (SPRC) surged 49% to $14.09 in pre-market trading, indicating strong investor interest likely driven by recent acquisition activities, which could enhance its market position.
- Other Gaining Stocks: Mobix Labs, Inc. (MOBX) rose 26% to $2.78, while Moolec Science SA. (MLEC) increased 14% to $9.22, reflecting positive sentiment in the biotech sector that may attract further investment.
- Pre-Market Decliners: ADC Therapeutics SA. (ADCT) plummeted 53% to $1.44, signaling market disappointment over its clinical trial results, which could lead to diminished investor confidence.
- Additional Declining Stocks: Basel Medical Group Ltd. (BMGL) fell 24% to $0.49, and Virax Biolabs Group Limited. (VRAX) dropped 17% to $0.19, highlighting the uncertainty in the biotech industry that may affect overall market sentiment.
See More
SciSparc Receives Approval to Acquire Stake in Israeli Tech Firm
- Acquisition Approval: SciSparc Ltd. (SPRC) received regulatory approval from the TSX Venture Exchange for its subsidiary NeuroThera Labs to acquire approximately 54% of CliniQuantum, valued at about $9.46 million, which is expected to enhance its competitive edge in clinical trial data analysis.
- Stock Surge: SPRC's shares soared nearly 140% to close at $10.55 on Thursday, reflecting strong market enthusiasm for its acquisition plans, which may attract further investor interest in its future growth prospects.
- Ebola Testing Progress: Co-Diagnostics Inc. (CODX) saw its stock rally over 50% for the third consecutive day amid the Ebola outbreak, indicating the effectiveness of its PCR assay strategy, which is likely to bolster the company's influence in public health.
- Clinical Trial Initiation: MiNK Therapeutics (INKT) dosed its first patient in a randomized phase 2 trial for acute lung injury, leading to an 18% stock increase, and this advancement could provide crucial data support for its future treatment options, strengthening its market position.
See More
SciSparc Subsidiary Receives Approval for CliniQuantum Acquisition
- Stock Surge: SciSparc Ltd. (SPRC) saw a 155% increase in stock price on Thursday, primarily driven by its subsidiary NeuroThera Labs receiving conditional approval from the TSX Venture Exchange for its acquisition, reflecting strong market optimism about the deal.
- Acquisition Details: NeuroThera plans to acquire approximately 54% of CliniQuantum in exchange for 56.6 million common shares, valued at about $9.46 million based on NeuroThera's 20-day volume-weighted average share price, indicating market recognition of its growth potential.
- Technological Innovation: CliniQuantum focuses on developing quantum simulation and Monte Carlo-based tools aimed at enhancing clinical trial precision by identifying patient subgroups most likely to respond to therapies, showcasing its cutting-edge position in clinical research.
- Exclusive Licensing Agreement: CliniQuantum's main asset is an exclusive worldwide license agreement with Quantum X Labs related to quantum simulation technologies for clinical trials, which will further strengthen its market competitiveness and drive future technological advancements.
See More
SciSparc Acquires Controlling Interest in CliniQuantum
- Transaction Overview: SciSparc's majority-owned NeuroThera Labs has signed a share purchase agreement to acquire approximately 54.01% of CliniQuantum's shares for about $9.45 million, with the transaction expected to close within 30 days, marking a strategic expansion into quantum technology.
- Share Payment Structure: NeuroThera will issue 56,600,000 common shares to the Selling Shareholders, who may also receive up to $2.5 million in earn-out payments based on CliniQuantum's patent applications and fundraising achievements, further incentivizing innovation.
- Technological Innovation Potential: CliniQuantum focuses on leveraging quantum computing to enhance clinical trials, aiming to accelerate research by processing complex datasets, and this acquisition will strengthen SciSparc's competitive edge in the pharmaceutical industry and drive cutting-edge product development.
- Future Outlook: The transaction is anticipated to close by March 31, 2026, providing SciSparc an opportunity to enhance its market position in treating central nervous system disorders and achieve long-term growth through technological integration.
See More
Clearmind Unveils Patent for Innovative Weight Loss Therapy
- Patent for Innovative Therapy: Clearmind Medicine Inc. has announced an international patent application for a novel therapy combining MEAI and Palmitoylethanolamide, aimed at treating obesity and metabolic dysfunction-associated steatotic liver disease, potentially benefiting over 890 million obese adults worldwide.
- Significant Market Potential: The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, indicating a strong demand for innovative alternatives, positioning Clearmind's new therapy to capture a share of this rapidly growing market.
- Strengthened Partnerships: The development of this therapy is bolstered by collaboration with NeuroThera Labs Inc., integrating Clearmind's MEAI platform with PEA to offer a safer and more cost-effective treatment option compared to GLP-1 agonists, enhancing the company's competitive edge in the biotech sector.
- Strategic Development Focus: CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to developing innovative therapies to address underserved metabolic and neurological health issues, further solidifying its leadership position in the biotechnology industry.
See More
